Bluebird Bio delays Zynteglo launch as manufacturing trips up another gene therapy
admin 19th June 2019 Uncategorised 0Once again, manufacturing concerns are delaying access to a new, highly anticipated, and very expensive gene therapy. Bluebird Bio, which this month got conditional European approval for its first gene therapy, says the launch will not occur until 2020 because regulators required it to “tighten up” its manufacturing before treating its first commercial patient.
More: Bluebird Bio delays Zynteglo launch as manufacturing trips up another gene therapy
Source: fierce